Prenatal Yoga for Postpartum Depression
(PRY-D Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Although psychological interventions exist for the prevention of PPD, a yoga-based intervention to prevent PPD among at-risk women utilizes a similar theoretical foundation (i.e., mindfulness), may be more acceptable to women of minority status, and may confer additional physical activity benefits. The purpose of this pilot study is to determine the effectiveness of using a virtually delivered prenatal yoga intervention for the prevention of PPD among at-risk women in a diverse health care system and explore preliminary factors which influence implementation of the intervention. This study has 2 phases: Phase 1 will evaluate facilitators and barriers to intervention implementation among patient, clinician, and health system stakeholders, followed by an open trial, and Phase 2 will include conducting an 8-session pilot randomized controlled trial to assess the feasibility and acceptability of the proposed prenatal yoga intervention among women with a history of depression, as well as the onset and course of PPD and mediating factors. The specific aims are to: 1) Optimize delivery of a yoga intervention within a healthcare system to prevent PPD through examining facilitators and barriers of implementation, 2) Examine feasibility, acceptability and satisfaction of the intervention within a health care system, and 3) Evaluate preliminary effectiveness of the intervention on PPD and proposed mechanisms. For Phase 1, separate focus groups with patient stakeholders and clinician and administrative stakeholders will inform intervention implementation, and an open trial to refine and optimize the intervention. For Phase 2, women with a history of depression who are 8-28 weeks pregnant will be randomized to the intervention group (n=24) or treatment-as-usual (n=24) and will complete survey measures at baseline, post-intervention, and 1 and 3 months postpartum. It is hypothesized that the intervention will be feasible and acceptable, engage women of racial/ethnic minority status, and contribute to lower rates of PPD onset. Embodiment and mindfulness are the proposed mediators. Knowledge gained from this study can support prevention efforts for PPD and improve the adverse public health impact of this disorder.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to consult with the trial coordinators or your healthcare provider for guidance.
Is prenatal yoga safe for pregnant women?
How is the Prenatal Yoga treatment different from other treatments for postpartum depression?
What data supports the effectiveness of the treatment Prenatal Yoga to Prevent Postpartum Depression (PRY-D)?
Who Is on the Research Team?
Amy M Loree, PhD
Principal Investigator
Henry Ford Health
Sara Santarossa, PhD
Principal Investigator
Henry Ford Health
Are You a Good Fit for This Trial?
This trial is for pregnant women aged 18 or older, between 8-28 weeks gestation, with a history of depression. They must be receiving prenatal care at Henry Ford Health and have an internet-enabled device with video capability to participate in virtual yoga classes.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Phase 1: Evaluation and Open Trial
Evaluate facilitators and barriers to intervention implementation and conduct an open trial to refine and optimize the intervention.
Phase 2: Pilot Randomized Controlled Trial
Conduct an 8-session pilot randomized controlled trial to assess the feasibility and acceptability of the prenatal yoga intervention.
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 1 and 3 months postpartum.
What Are the Treatments Tested in This Trial?
Interventions
- Prenatal Yoga to Prevent Postpartum Depression (PRY-D) intervention
Prenatal Yoga to Prevent Postpartum Depression (PRY-D) intervention is already approved in United States, India, European Union for the following indications:
- Prevention of Postpartum Depression
- Prevention of Postpartum Depression
- Reduction of Anxiety in Pregnancy
- Prevention of Postpartum Depression
- Improvement of Mental Health in Pregnancy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Henry Ford Health System
Lead Sponsor
National Institute of Mental Health (NIMH)
Collaborator
University of Colorado, Boulder
Collaborator